GEM PHARMACEUTICALS
Gem Pharmaceuticals, LLC, is a clinical-stage biopharmaceutical company developing proprietary anthracycline derivatives specifically designed to eliminate the critical cardiotoxicity side effect of this powerful class of chemotherapeutics while maintaining their well-documented anti-cancer efficacy.
GEM PHARMACEUTICALS
Industry:
Biopharma Biotechnology Pharmaceutical
Founded:
2003-01-01
Address:
Birmingham, Alabama, United States
Country:
United States
Website Url:
http://www.gempharmaceuticals.com
Total Employee:
1+
Status:
Active
Contact:
205-982-8383
Total Funding:
4.5 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible Apache ReCAPTCHA GoDaddy Network Solutions DNS Starfield Technologies
Similar Organizations
AZTherapies
AZTherapies is a clinical stage biotech company developing breakthrough treatments for neuroinflammation-related diseases.
Celator Pharmaceuticals
Celator Pharmaceuticals is a biopharmaceutical company developing therapies to treat cancer, using the drug ratio technology platform.
Proteostasis Therapeutics
Proteostasis Therapeutics is a clinical stage biopharmaceutical company developing small molecule therapeutics to treat cystic fibrosis.
Reata Pharmaceuticals
Reata Pharmaceuticals is a biopharmaceutical company that develops drugs for cancer, inflammation, and neurodegenerative diseases.
Sparrow Pharmaceuticals
Sparrow Pharmaceuticals is a clinical-stage biopharmaceutical company developing treatments for disorders of corticosteroid excess.
Current Employees Featured
Founder
Investors List
Diane Hendricks
Diane Hendricks investment in Venture Round - Gem Pharmaceuticals
Karl Leo
Karl Leo investment in Venture Round - Gem Pharmaceuticals
Official Site Inspections
http://www.gempharmaceuticals.com
- Host name: 130.12.180.107.host.secureserver.net
- IP address: 107.180.12.130
- Location: Scottsdale United States
- Latitude: 33.6013
- Longitude: -111.8867
- Metro Code: 753
- Timezone: America/Phoenix
- Postal: 85260
More informations about "Gem Pharmaceuticals"
Gem Pharmaceuticals - Crunchbase Company Profile
Gem Pharmaceuticals, LLC, is a clinical-stage biopharmaceutical company developing proprietary anthracycline derivatives specifically designed to …See details»
Gem Pharmaceuticals Company Profile 2024: Valuation, …
Information on acquisition, funding, investors, and executives for Gem Pharmaceuticals. Use the PitchBook Platform to explore the full profile.See details»
Gem Pharmaceuticals LLC - Company Profile and News
Company profile page for Gem Pharmaceuticals LLC including stock price, company news, executives, board members, and contact informationSee details»
Gem Pharmaceuticals - Company Profile - Tracxn
Nov 27, 2024 Gem Pharmaceuticals - Specialty company developing anthracycline derivatives to eliminate cardiotoxicity side effect. Raised a total funding of $4.5M over 1 round from 1 …See details»
Organization | Gem Pharmaceuticals - Purdue University
Gem Pharmaceuticals Report issue For profit Phase 2 Founded: Birmingham AL United States (2003) Status: Acquired by Monopar Therapeutics (2017) Organization Overview First Clinical …See details»
Gem Pharmaceuticals Management Team | Org Chart - RocketReach
Gem Pharmaceuticals is a pharmaceuticals company based out of 941 Lake Forest Cir, Birmingham, Alabama, United States.See details»
Gem Pharmaceuticals - Products, Competitors, Financials, …
Gem Pharmaceuticals is a clinical-stage biopharmaceutical company developing anthracycline derivatives specifically designed to eliminate the critical cardiotoxicity side effect of this …See details»
Gem Pharmaceuticals - VentureRadar
Gem Pharmaceuticals is a clinical-stage biopharmaceutical company developing proprietary anthracycline derivatives specifically designed to eliminate the critical cardiotoxicity side effect …See details»
Gem Pharmaceuticals - Ownership and Business Overview - Mergr
GEM Pharmaceuticals is a biopharmaceutical company engaged in the development and commercialization of novel anthracycline for the treatment of cancers and inflammation. The …See details»
Gem Pharmaceuticals LLC - BioCentury Company Profiles - BCIQ
Gem Pharmaceuticals LLC - BioCentury Company Profiles for the biopharma industrySee details»
Gem Pharmaceuticals Profile and History - Datanyze
Find contact information for Gem Pharmaceuticals. Learn about their Manufacturing, Pharmaceuticals market share, competitors, and Gem Pharmaceuticals's email format.See details»
Gem Pharmaceuticals - Funding, Financials, Valuation & Investors
Gem Pharmaceuticals, LLC, is a clinical-stage biopharmaceutical company developing proprietary anthracycline derivatives specificallySee details»
Gem Pharmaceuticals LLC: Drug pipelines, Patents, Clinical trials
Aug 2, 2023 Explore Gem Pharmaceuticals LLC with its drug pipeline, therapeutic area, technology platform, 4 clinical trials, 1 news, Disease Domain:Neoplasms, Technology ...See details»
Gem Pharmaceuticals - Tech Company Profile - Gaebler.com …
Gem Pharmaceuticals, LLC, is a clinical-stage biopharmaceutical company developing proprietary anthracycline derivatives.See details»
Gem Pharmaceuticals - Crunchbase
Gem Pharmaceuticals, LLC, is a clinical-stage biopharmaceutical company developing proprietary anthracycline derivatives specificallySee details»
Gem Pharmaceuticals Information - RocketReach
Gem Pharmaceuticals is a Biotechnology, Pharmaceutical Manufacturing, and Drug Manufacturing & Research company_reader located in Birmingham, Alabama with $412000 in …See details»
GEM PHARMACEUTICALS - Dun & Bradstreet
Find company research, competitor information, contact details & financial data for GEM PHARMACEUTICALS of Hyderabad, Telangana. Get the latest business insights from Dun & …See details»
Gem Pharmaceuticals - 7C558 - GovTribe
Gem Pharmaceuticals - 7C558 Federal Contract and Grant Award History. 7C558. Partnership or Limited Liability Partnership. For Profit OrganizationSee details»
Gem Pharmaceuticals Announces $4.5-Million Financing for Phase …
Gem Pharmaceuticals recently announced that current Gem board members/investors Diane Hendricks and Karl Leo have agreed to provide up to $4.5 million in new capital in order to …See details»